The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Bristol-Myers Squibb beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly and GAAP earnings per share increased.
Gross margins dropped, operating margins shrank, net margins expanded.
Bristol-Myers Squibb tallied revenue of $4.19 billion. The 12 analysts polled by S&P Capital IQ expected a top line of $4.14 billion on the same basis. GAAP reported sales were 23% lower than the prior-year quarter's $5.45 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.47. The 16 earnings estimates compiled by S&P Capital IQ anticipated $0.43 per share. GAAP EPS of $0.56 for Q4 were 12% higher than the prior-year quarter's $0.50 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 74.3%, 90 basis points worse than the prior-year quarter. Operating margin was 12.2%, 1,720 basis points worse than the prior-year quarter. Net margin was 22.1%, 650 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $3.93 billion. On the bottom line, the average EPS estimate is $0.44.
Next year's average estimate for revenue is $16.59 billion. The average EPS estimate is $1.84.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,704 members out of 1,815 rating the stock outperform, and 111 members rating it underperform. Among 505 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 486 give Bristol-Myers Squibb a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.50.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. TMFDisclosureHere